Baidu
map

Eur J Neurol:卒中或TIA后,短期双联抗血小板作用优于长期治疗

2016-04-10 MedSci MedSci原创

背景:在2014年,推荐应用阿司匹林和氯吡格雷联合抗血小板(DAPT)治疗90天作为轻型缺血性卒中或短暂性脑缺血发作(TIA)的二级预防。但是,是否持续应用90天对每个患者都适用尚不清楚。因此,通过系统性综述和荟萃分析评估卒中或TIA后短期(≤3个月)和长期(≥1年)DAPT治疗的安全性和有效性。方法:搜索Cochrane图书馆,Clinical Trials.gov和PubMed,检索至2014

背景:在2014年,推荐应用阿司匹林和氯吡格雷联合抗血小板(DAPT)治疗90天作为轻型缺血性卒中或短暂性脑缺血发作(TIA)的二级预防。但是,是否持续应用90天对每个患者都适用尚不清楚。因此,通过系统性综述和荟萃分析评估卒中或TIA后短期(≤3个月)和长期(≥1年)DAPT治疗的安全性和有效性。

方法:搜索Cochrane图书馆,Clinical Trials.gov和PubMed,检索至2014年12月。共有九个随机对照实验,包括21 923例患者。

结果:短期DAPT治疗缺血性卒中复发降低41%、主要血管事件发生降低风险30%,不增加颅内出血的风险。延长DAPT治疗缺血性卒中复发降低12%、主要血管事件风险降低10%。然而,大出血和颅内出血的风险增加。

结论:短期治疗似乎优于延长DAPT。然而,疗效结果的差异需要进行仔细的解释,并精心设计随机对照试验进行证实。

原文出处:

Ge F, Lin H, et al. Dual antiplatelet therapy after stroke or transient ischaemic attack - how long to treat? The duration of aspirin plus clopidogrel in stroke or transient ischaemic attack: a systematic review and meta-analysis.
Eur J Neurol. 2016 Mar 28.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1999676, encodeId=343c19996e64a, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Oct 31 09:14:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009516, encodeId=32b12009516b8, content=<a href='/topic/show?id=4f133e56590' target=_blank style='color:#2F92EE;'>#双联抗血小板#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37565, encryptionId=4f133e56590, topicName=双联抗血小板)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Mon Oct 03 04:14:00 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055541, encodeId=0aa1205554136, content=<a href='/topic/show?id=4ebf9e016c6' target=_blank style='color:#2F92EE;'>#长期治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97016, encryptionId=4ebf9e016c6, topicName=长期治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sat Dec 03 15:14:00 CST 2016, time=2016-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78087, encodeId=cb0de80871c, content=高大上的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:28:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78088, encodeId=87abe80883a, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:28:00 CST 2016, time=2016-04-14, status=1, ipAttribution=)]
    2016-10-31 yinhl1978
  2. [GetPortalCommentsPageByObjectIdResponse(id=1999676, encodeId=343c19996e64a, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Oct 31 09:14:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009516, encodeId=32b12009516b8, content=<a href='/topic/show?id=4f133e56590' target=_blank style='color:#2F92EE;'>#双联抗血小板#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37565, encryptionId=4f133e56590, topicName=双联抗血小板)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Mon Oct 03 04:14:00 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055541, encodeId=0aa1205554136, content=<a href='/topic/show?id=4ebf9e016c6' target=_blank style='color:#2F92EE;'>#长期治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97016, encryptionId=4ebf9e016c6, topicName=长期治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sat Dec 03 15:14:00 CST 2016, time=2016-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78087, encodeId=cb0de80871c, content=高大上的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:28:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78088, encodeId=87abe80883a, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:28:00 CST 2016, time=2016-04-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1999676, encodeId=343c19996e64a, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Oct 31 09:14:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009516, encodeId=32b12009516b8, content=<a href='/topic/show?id=4f133e56590' target=_blank style='color:#2F92EE;'>#双联抗血小板#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37565, encryptionId=4f133e56590, topicName=双联抗血小板)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Mon Oct 03 04:14:00 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055541, encodeId=0aa1205554136, content=<a href='/topic/show?id=4ebf9e016c6' target=_blank style='color:#2F92EE;'>#长期治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97016, encryptionId=4ebf9e016c6, topicName=长期治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sat Dec 03 15:14:00 CST 2016, time=2016-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78087, encodeId=cb0de80871c, content=高大上的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:28:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78088, encodeId=87abe80883a, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:28:00 CST 2016, time=2016-04-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1999676, encodeId=343c19996e64a, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Oct 31 09:14:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009516, encodeId=32b12009516b8, content=<a href='/topic/show?id=4f133e56590' target=_blank style='color:#2F92EE;'>#双联抗血小板#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37565, encryptionId=4f133e56590, topicName=双联抗血小板)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Mon Oct 03 04:14:00 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055541, encodeId=0aa1205554136, content=<a href='/topic/show?id=4ebf9e016c6' target=_blank style='color:#2F92EE;'>#长期治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97016, encryptionId=4ebf9e016c6, topicName=长期治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sat Dec 03 15:14:00 CST 2016, time=2016-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78087, encodeId=cb0de80871c, content=高大上的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:28:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78088, encodeId=87abe80883a, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:28:00 CST 2016, time=2016-04-14, status=1, ipAttribution=)]
    2016-04-14 李继凯

    高大上的文章

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1999676, encodeId=343c19996e64a, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Oct 31 09:14:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009516, encodeId=32b12009516b8, content=<a href='/topic/show?id=4f133e56590' target=_blank style='color:#2F92EE;'>#双联抗血小板#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37565, encryptionId=4f133e56590, topicName=双联抗血小板)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Mon Oct 03 04:14:00 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055541, encodeId=0aa1205554136, content=<a href='/topic/show?id=4ebf9e016c6' target=_blank style='color:#2F92EE;'>#长期治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97016, encryptionId=4ebf9e016c6, topicName=长期治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sat Dec 03 15:14:00 CST 2016, time=2016-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78087, encodeId=cb0de80871c, content=高大上的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:28:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78088, encodeId=87abe80883a, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:28:00 CST 2016, time=2016-04-14, status=1, ipAttribution=)]
    2016-04-14 李继凯

    值得学习

    0

相关资讯

Sci Rep:CEE治疗可增加台湾更年期女性发生房颤的风险

激素替代疗法(HRT)与血管疾病风险相关。先前研究显示:心房颤动(AF),血管事件和不同的HRTs,包括雌二醇和共轭雌激素(CEE)相关性的研究存在争议。因此,研究者进行回顾性队列研究,以调查相关性。台湾的研究者从国家健康保险研究数据库(1998-2008)中招募首次确诊为更年期的女性患者(>45岁)。应用Cox回归分析评估应用雌二醇或CEE治疗后,受试者新发房颤、卒中和主要不良心脏事件(MACE

Neurology:应用他汀类药物可降低卒中后出血的风险

目标:评估急性缺血性卒中(AIS)发生前后应用他汀类药物治疗对急性脑出血(ICH)的风险,急性后期ICH的风险及90天死亡率的影响。方法:研究者从虚拟国际卒中试验档案(VISTA)这一国际资料库的临床试验数据中选取数据。应用倾向评分匹配,研究者回顾性比较先前应用他汀治疗的患者和AIS后3天开始应用他汀类治疗的患者。主要预后为急性症状型ICH(sICH),任何急性ICH,急性后期ICH和随访3个月的

Cerebrovasc Dis:穿支动脉粥样硬化疾病:一个具有临床意义,但还未经检验的概念

在1989年,Louis Caplan第一次使用了穿支动脉粥样硬化疾病(BAD)这一术语来描述大脑深穿支动脉起始部分的狭窄或闭塞,与小动脉粥样硬化或开口处斑块相关,可以导致内囊或者脑桥的小梗死。数十年来BAD仍然是一个未被研究的概念。最近数年,高分辨率磁共振技术的与日扩散带来了对BAD争论的新的关注。我们回顾了和BAD相关的卒中的临床研究,来发现一个BAD的明确定义,以及临床及影像特点报道一致性的

ACC 2016:GlycA水平可预测民众患心血管疾病和卒中风险

2016年美国心脏病学会科学会议提出,如果机体动脉血液中含有高水平炎症标记物,则高水平高密度脂蛋白不能保护人们免受心脏病的困扰。动脉壁的炎症会增加民众出现心脏病或卒中的风险,因为它增加了动脉壁斑块破裂的风险。动脉斑块一旦破裂,则会导致血栓的形成和血管的闭塞。 胆固醇是一种脂肪物质。人体需要适量的胆固醇,但是如果胆固醇含量太高,它可以聚集在动脉,从而导致民众出现心脏病和卒中。低密度脂蛋白(LDL)—

Int J Cardiol:识别卒中患者发生房颤的模型

背景和目的:急性脑卒中患者发生房颤的风险较高。这篇研究的目的旨在构建一个模型,可以预测急性缺血性卒中患者,房颤的存在,并且验证此模型。方法:研究者参与实验的两个医院中,收集基于医院的卒中登记记录,研究者选取症状开始24h内的患者。应用1355个急性缺血性卒中患者的数据,构建预测房颤的存在的模型,并且统计可能发生房颤的概率。根据房颤的发生可能,将患者分为低危,中危和高危组。调查并验证急性缺血性卒中患

Neurology: 卒中护理综合系统可降低卒中患者30天死亡率

背景:评估加拿大卒中护理综合系统与卒中病死率之间的相关性。方法:加拿大的研究者应用加拿大健康信息出院摘要数据库,识别2003 / 2004年到2013 / 2014年这11个财政年度,除魁北克省入院到所有急性护理医院的卒中/ TIA患者。研究者应用改良Poisson回归模型,校正年龄,性别、卒中类型、合并症,出院年份,计算与无卒中患者相比,卒中患者30天的住院死亡率的aIRR。研究者对2009年和

Baidu
map
Baidu
map
Baidu
map